Cargando…
UNC13B Promote Arsenic Trioxide Resistance in Chronic Lymphoid Leukemia Through Mitochondria Quality Control
In clinical practice, arsenic trioxide can be used to treat a subset of R/R CML patients, but resistance tends to reappear quickly. We designed an experiment to study arsenic trioxide resistance in K-562 cells. Previously, we identified the UNC13B gene as potentially responsible for arsenic trioxide...
Autores principales: | Wang, Xiao-Bo, Yuan, Li-Hua, Yan, Le-Ping, Ye, Yong-Bin, Lu, Bo, Xu, Xiaojun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190243/ https://www.ncbi.nlm.nih.gov/pubmed/35707364 http://dx.doi.org/10.3389/fonc.2022.920999 |
Ejemplares similares
-
Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis
por: Tinajero, Jose, et al.
Publicado: (2022) -
Arsenic Trioxide Therapy During Pregnancy: ATO and Its Metabolites in Maternal Blood and Amniotic Fluid of Acute Promyelocytic Leukemia Patients
por: Guo, Meihua, et al.
Publicado: (2022) -
Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment
por: Chen, Baowei, et al.
Publicado: (2013) -
A Review of Arsenic Trioxide and Acute Promyelocytic Leukemia
por: Alimoghaddam, Kamran
Publicado: (2014) -
On arsenic trioxide in the clinical treatment of acute promyelocytic leukemia
por: Zhang, Peng
Publicado: (2017)